Tag : ALK

CONFERENCE UPDATE

First-line lorlatinib continues to show PFS benefit over crizotinib in patients with advanced ALK+ NSCLC: 5-year follow-up of the CROWN study
Lorlatinib is a brain-penetrant third-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) which covers a broader ALK resistance profile than second-generation ALK TKIs. It has previously demonstrated improved PFS and IC activity compared to crizotinib in treatment-naïve patients with advanced ALK+ NSCLC in the ongoing randomized phase 3 CROWN study.